What are the Historical Developments and Current Growth Metrics of the Protein Degradation Therapy Market?
The protein degradation therapy market has seen considerable growth due to a variety of factors.
• In the past few years, there has been a robust growth in the market size of protein degradation therapy. Its estimated value is expected to surge from $1.16 billion in 2024 to about $1.25 billion in 2025, exhibiting a compound annual growth rate (CAGR) of 8.2%.
The upswing during the historical phase is largely due to reasons like higher incidence of neurodegenerative illnesses, improved success rate of targeted therapies, amplified investments in biotech innovation, escalating demand for personalized medicinal treatment, and limitations of traditional therapies in treating some diseases.
What Does Future Hold for The Protein Degradation Therapy Market By 2029?
The protein degradation therapy market is expected to maintain its strong growth trajectory in upcoming years.
• The market for protein degradation therapy is poised for robust expansion in the upcoming years, reaching a valuation of $1.7 billion in 2029, witnessing a compound annual growth rate (CAGR) of 7.9%.
Factors contributing to this predicted growth during the forecast period include a rising incidence of chronic diseases, an increase in biotech research investments, a surging demand for targeted treatments, the proliferation of clinical trials, and favourable regulatory circumstances. Key trends projected for the forecast period encompass the creation of next-generation PROTACs, the incorporation of artificial intelligence and machine learning, the introduction of combination therapies, the creation of customized protein degradation remedies, and advancements in oral formulation and drug delivery techniques.
What Are The Primary Growth Drivers In The Protein Degradation Therapy Market?
The escalating incidence of cancer is projected to fuel the expansion of the protein degradation therapy market. Cancer encompasses various diseases characterized by unregulated growth and spread of abnormal cells in the body. The surge in cancer rates can be attributed primarily to a mix of elements, of which the aging population plays a noteworthy part. Moreover, lifestyle factors such as smoking, unhealthy eating habits, sedentary lifestyle, and the increasing instances of obesity have enhanced the likelihood of numerous types of cancer. Protein degradation therapy, which targets and eradicates specific proteins that stimulate cancer growth and survival, is essential in cancer treatment and could potentially lead to overcoming resistance to conventional treatments. For example, a report published by the World Health Organization, a Switzerland-based intergovernmental organization, in February 2024, predicts more than 35 million new cancer diagnoses in 2050, marking a 77% rise from the approximate 20 million in 2022. Furthermore, countries with high human development index (HDI) are anticipated to witness the most significant increment in absolute figures, with an added 4.8 million new cases projected for 2050 in comparison with 2022 assessments. Consequently, the escalating incidence of cancer is fostering the expansion of the protein degradation therapy market.
What Is The Segmentation Of The Global Protein Degradation Therapy Market?
The protein degradation therapy market covered in this report is segmented –
1) By Type: Bavdegalutamide (ARV - 110); Vepdegestrant (ARV - 471); Other Types
2) By Application: Oncology; Neurodegenerative Diseases; Infectious Diseases; Other Applications
3) By End-User: Pharmaceutical Companies; Biotechnology Companies; Academic And Research Institutes
Subsegment:
1) By Bavdegalutamide (ARV-110): Androgen Receptor Degraders; Prostate Cancer Therapy
2) By Vepdegestrant (ARV-471): Estrogen Receptor Degraders; Breast Cancer Therapy
Pre-Book The Protein Degradation Therapy Global Market Report 2025 Report For Swift Delivery And Comprehensive Insights:
Which Emerging Market Trends Are Altering The Protein Degradation Therapy Industry?
Top-tier companies in the protein degradation therapy market are establishing strategic partnerships for nurturing innovative medicinal therapies, consolidating complementary skills, distributing resources, and expediting the process of discovering and developing unprecedented drug candidates that target proteins that cause diseases. Strategic alliances refer to businesses utilizing each other's capabilities and resources to attain reciprocal advantages and accomplish joint triumphs. For example, in June 2022, a strategic partnership was formed between Merck KGaA, a science and technology firm based in Germany, and Proxygen, a biotechnology firm situated in Austria, for a significant, long-term research collaboration and licensing agreement to shape molecular glue degraders. The deal is worth up to $2.55 billion, incorporating an upfront payment and potential payments upon reaching certain research, development, and commercial goals. The alliance will utilize Proxygen's proficiency in designing molecular glue degraders that aim to selectively eradicate disease-causing proteins, an approach that opens novel pathways for therapeutic development by targeting proteins that are typically deemed "undruggable" by conventional modalities.
Who Are the Key Players In The Protein Degradation Therapy Market?
Major companies operating in the protein degradation therapy market are:
• Relay Therapeutics
• Arvinas Holding Company LLC
• Kymera Therapeutics
• Nurix Therapeutics
• Vividion Therapeutics
• Mission Therapeutics Ltd.
• C4 Therapeutics Inc.
• Cullgen Inc.
• Frontier Medicines
• Foghorn Therapeutics
• Aileron Therapeutics
• Ribometrix Inc.
• Nimbus Therapeutics
• Jnana Therapeutics
• KSQ Therapeutics
• Stoke Therapeutics
• Flare Therapeutics
• Accent Therapeutics
• Monte Rosa Therapeutics
• Lycia Therapeutics
• Dialectic Therapeutics
• Amphista Therapeutics
• Biotheryx Inc.
• Cedilla Therapeutics
• Dewpoint Therapeutics Inc
What Are The Regional Insights Into The Protein Degradation Therapy Market?
North America was the largest region in the protein degradation therapy market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the protein degradation therapy market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
